Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
This paper, co-authored by European psychedelic researchers as well as European Medicines Agency representatives was recently published. It outlines key knowledge gaps “that may be imperative for a successful implementation of psychedelic drugs as medicines”. It provides a summary of topics discussed at the European College of Neuropsychopharmacology at the New Frontiers Meeting in Nice and paves the way for the upcoming EMA workshop on psychedelics.